Health Economics Research Centre (HERC)
@herc-oxford.bsky.social
Health Economics Research Centre | University of Oxford | Research, publications, courses, jobs, seminars | https://www.herc.ox.ac.uk/
2/2 Our Poster ‘The HERC Database of Mapping Studies’ MSR199 is in Session 4 (tomorrow at 9am) #ISPOREurope.
ispor.org/conferences-...
#HERC #HERCMappingDatabase
ispor.org/conferences-...
#HERC #HERCMappingDatabase
The HERC Database of Mapping Studies: A 2025 Update of a Live Systematic Review of Studies Predicting EQ-5D From Other Patient-Reported Outcome Measures
ispor.org
November 11, 2025 at 10:26 AM
2/2 Our Poster ‘The HERC Database of Mapping Studies’ MSR199 is in Session 4 (tomorrow at 9am) #ISPOREurope.
ispor.org/conferences-...
#HERC #HERCMappingDatabase
ispor.org/conferences-...
#HERC #HERCMappingDatabase
Two #ISPOREurope posters on the #HERC Database of Mapping Studies will be in Glasgow next week: MSR176 in Session 4 (Tues 11th 6pm); MSR199 in Session 5 (Wed 12th, 9am). #HERCMappingDatabase #EQ5D
November 7, 2025 at 3:30 PM
Two #ISPOREurope posters on the #HERC Database of Mapping Studies will be in Glasgow next week: MSR176 in Session 4 (Tues 11th 6pm); MSR199 in Session 5 (Wed 12th, 9am). #HERCMappingDatabase #EQ5D
3/3 ... from data-rich regions and improve predictions in countries with sparse surveillance information. This makes it a valuable tool for improving antibiotic decisions, especially in low-resource settings, and helps reduce the use of overly broad antibiotics.
October 22, 2025 at 10:58 AM
3/3 ... from data-rich regions and improve predictions in countries with sparse surveillance information. This makes it a valuable tool for improving antibiotic decisions, especially in low-resource settings, and helps reduce the use of overly broad antibiotics.
2/3 The team used advanced modelling techniques to provide more insight into when to escalate antibiotic treatment compared to conventional techniques. Their approach allows for partial pooling of information across countries, enabling the model to “borrow strength” ...
October 22, 2025 at 10:58 AM
2/3 The team used advanced modelling techniques to provide more insight into when to escalate antibiotic treatment compared to conventional techniques. Their approach allows for partial pooling of information across countries, enabling the model to “borrow strength” ...
Link to paper: journals.sagepub.com/doi/10.1177/...
Lottery or Triage? Controlled Experimental Evidence from the COVID-19 Pandemic on Public Preferences for Allocation of Scarce Medical Resources - Rhys Llewellyn Thomas, Laurence SJ Roope, Raymond Duch...
Background Bioethicists have advocated lotteries to distribute scarce health care resources, highlighting the benefits that make them attractive amid growing he...
journals.sagepub.com
October 21, 2025 at 12:18 PM
Link to paper: journals.sagepub.com/doi/10.1177/...
5/5
If you register for more than one Online-only course you will receive a 20% reduction on the overall cost. Further discounts are available to prospective participants from Lower to Middle-Income countries.
If you register for more than one Online-only course you will receive a 20% reduction on the overall cost. Further discounts are available to prospective participants from Lower to Middle-Income countries.
October 7, 2025 at 10:20 AM
5/5
If you register for more than one Online-only course you will receive a 20% reduction on the overall cost. Further discounts are available to prospective participants from Lower to Middle-Income countries.
If you register for more than one Online-only course you will receive a 20% reduction on the overall cost. Further discounts are available to prospective participants from Lower to Middle-Income countries.
4/5
Cost-effectiveness Analysis in Stata Using Participant-level Data 02-04 December (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
Cost-effectiveness Analysis in Stata Using Participant-level Data 02-04 December (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
Cost-effectiveness Analysis in Stata Using Participant-level Data
www.herc.ox.ac.uk
October 7, 2025 at 10:19 AM
4/5
Cost-effectiveness Analysis in Stata Using Participant-level Data 02-04 December (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
Cost-effectiveness Analysis in Stata Using Participant-level Data 02-04 December (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
3/5
Applied Methods of Cost-Effectiveness Analysis 24-28 November (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
Applied Methods of Cost-Effectiveness Analysis 24-28 November (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
Applied Methods of Cost-Effectiveness Analysis
www.herc.ox.ac.uk
October 7, 2025 at 10:18 AM
3/5
Applied Methods of Cost-Effectiveness Analysis 24-28 November (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
Applied Methods of Cost-Effectiveness Analysis 24-28 November (online)
#healtheconomics
www.herc.ox.ac.uk/herc-short-c...
2/5
Online: Inequality in Health and Health Care: Theoretical and Empirical Considerations 05-07 November
www.herc.ox.ac.uk/herc-short-c...
Online: Inequality in Health and Health Care: Theoretical and Empirical Considerations 05-07 November
www.herc.ox.ac.uk/herc-short-c...
Inequality in Health and Health Care: Theoretical and Empirical Considerations
www.herc.ox.ac.uk
October 7, 2025 at 10:17 AM
2/5
Online: Inequality in Health and Health Care: Theoretical and Empirical Considerations 05-07 November
www.herc.ox.ac.uk/herc-short-c...
Online: Inequality in Health and Health Care: Theoretical and Empirical Considerations 05-07 November
www.herc.ox.ac.uk/herc-short-c...
3/4 The episode includes: * Challenges of conducting economic evaluations in personalised medicine * What outcomes are important to patients and families * Complexity of evaluating gene therapies and genomic newborn screening * Reimbursement strategies and policy implications
October 6, 2025 at 1:13 PM
3/4 The episode includes: * Challenges of conducting economic evaluations in personalised medicine * What outcomes are important to patients and families * Complexity of evaluating gene therapies and genomic newborn screening * Reimbursement strategies and policy implications